SELLAS Life Sciences Group Inc.(SLS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

SLS SELLAS Life Sciences Group Inc.

Pre-Mkt 05-13 07:56:24 EDT

5.22

-0.03

-0.57%

盘前6.18

+0.96+18.32%

07:56 EDT

High5.28	Low5.03	Vol5.90M
Open5.22	D1 Closing5.25	Amplitude4.86%
Mkt Cap963.26M	Tradable Cap960.48M	Total Shares184.53M
T/O30.58M	T/O Rate3.21%	Tradable Shares184.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"SLS","market":"US","secType":"STK","nameCN":"SELLAS Life Sciences Group Inc.","latestPrice":5.22,"timestamp":1778616000000,"preClose":5.25,"halted":0,"volume":5902700,"hourTrading":{"tag":"盘前","latestPrice":6.1761,"preClose":5.22,"latestTime":"07:56 EDT","volume":499446,"amount":3117349.6452900004,"timestamp":1778673376151,"change":0.9561,"changeRate":0.183161,"amplitude":0.151092},"delay":0,"changeRate":-0.005714285714285762,"floatShares":184000000,"shares":184532574,"eps":-0.246333,"marketStatus":"Pre-Mkt","change":-0.03,"latestTime":"05-13 07:56:24 EDT","open":5.22,"high":5.28,"low":5.025,"amount":30583314.202049997,"amplitude":0.048571,"askPrice":6.2,"askSize":2000,"bidPrice":6.13,"bidSize":314,"shortable":3,"etf":0,"ttmEps":-0.246333,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1778679000000},"marketStatusCode":1,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":5.22,"preHourTrading":{"tag":"盘前","latestPrice":6.1761,"preClose":5.22,"latestTime":"07:56 EDT","volume":499446,"amount":3117349.6452900004,"timestamp":1778673376151,"change":0.9561,"changeRate":0.183161,"amplitude":0.151092},"postHourTrading":{"tag":"盘后","latestPrice":6.05,"preClose":5.22,"latestTime":"19:59 EDT","volume":3082804,"amount":18971424.3339,"timestamp":1778630399255,"change":0.83,"changeRate":0.159004,"amplitude":0.281609},"volumeRatio":1.4518302131204068,"impliedVol":0.6947,"impliedVolPercentile":0.064},"requestUrl":"/m/hq/s/SLS","defaultTab":"news","newsList":[{"id":"2635229374","title":"Stocks to Watch: NextPower, Sellas, System1, Arteris","url":"https://stock-news.laohu8.com/highlight/detail?id=2635229374","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635229374?lang=en_us&edition=fundamental","pubTime":"2026-05-13 07:12","pubTimestamp":1778627520,"startTime":"0","endTime":"0","summary":"NextPower raised its sales outlook and said it plans to make an acquisition to support its entry into the power-conversion industry. The stock gained 11% to $138.91 in after-hours trading Tuesday.Sellas Life Sciences said one of its trials is close to being ready for a data review. The stock climbed 13% to $5.88 after the bell.System1 said its revenue halved during the first quarter. Shares slid 27% to $3.25 in late trade.Arteris raised its full-year revenue outlook. Shares rose 9% to $35.39.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2249611893.SGD","BK4077","LU2275660780.HKD","LU2298322129.HKD","LU2294711713.HKD","SST","LU0724618433.USD","BK4139","BK4097","NXT","BK4585","LU0728928796.USD","LU1978683503.SGD","BK4096","SLS","LU0302445910.USD","LU1983299162.USD","LU0124384867.USD","BK4588","BK4596","LU0053671581.USD","LU0823414478.USD","AIP","LU2506951792.HKD","LU0823414551.USD","LU2357125470.USD","LU0312595415.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635338226","title":"Sellas Life Sciences Shares Climb as Trial Nears Data Review","url":"https://stock-news.laohu8.com/highlight/detail?id=2635338226","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635338226?lang=en_us&edition=fundamental","pubTime":"2026-05-13 06:17","pubTimestamp":1778624220,"startTime":"0","endTime":"0","summary":"Sellas Life Sciences shares rose after the company said its Phase 3 trial is nearly ready for data review.The stock gained 13% to $5.91 in after-hours trading. Through the close, the stock was up 38% year to date.The late-stage clinical biopharmaceutical company's Phase 3 trial evaluating Galinpepimut-S as a treatment for leukemia requires 80 pre-specified events to lock the database and start analyzing it.As of May 11, 78 events had occurred, Sellas said. The company plans to provide an update when the 80th event happens.Sellas also said its loss widened to $8.4 million, or 5 cents a share, compared with a loss of $5.8 million, or 7 cents a share, in the year-ago quarter.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SLS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635223360","title":"SELLAS Life Sciences Gr Q1 EPS $(0.05) Beats $(0.06) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2635223360","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635223360?lang=en_us&edition=fundamental","pubTime":"2026-05-13 05:05","pubTimestamp":1778619931,"startTime":"0","endTime":"0","summary":"SELLAS Life Sciences Gr (NASDAQ:SLS) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $(0.06) by 16.67 percent. This is a 28.57 percent increase over losses of $(0.07) per share","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/05/52508843/sellas-life-sciences-gr-q1-eps-0-05-beats-0-06-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"SELLAS Life Sciences Gr Q1 EPS $(0.05) Beats $(0.06) Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SLS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635983228","title":"SELLAS Life Sciences Group Q1 Loss Narrows","url":"https://stock-news.laohu8.com/highlight/detail?id=2635983228","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635983228?lang=en_us&edition=fundamental","pubTime":"2026-05-13 04:44","pubTimestamp":1778618688,"startTime":"0","endTime":"0","summary":"SELLAS Life Sciences Group  reported a Q1 loss late Tuesday of $0.05 per diluted share, narrowing from a loss of $0.07 a year earlier.Two analysts polled by FactSet expected a loss of $0.06.Cash and cash equivalents were $107.1 million at the end of Q1, compared with $71.8 million at the end of Q4.Shares of the company rose more than 12% in after-hours activity.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SLS","SLS.AU","BK4139","BK7104"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635240773","title":"Earnings Flash (SLS) SELLAS Life Sciences Posts Q1 Loss $0.05, vs. FactSet Est of $0.06 Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2635240773","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635240773?lang=en_us&edition=fundamental","pubTime":"2026-05-13 04:31","pubTimestamp":1778617888,"startTime":"0","endTime":"0","summary":"Earnings Flash (SLS) SELLAS Life Sciences Posts Q1 Loss $0.05, vs. FactSet Est of $0.06 Loss","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SLS.AU","SLS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635240584","title":"SELLAS Life Sciences Q1 net loss widens on higher expenses","url":"https://stock-news.laohu8.com/highlight/detail?id=2635240584","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635240584?lang=en_us&edition=fundamental","pubTime":"2026-05-13 04:19","pubTimestamp":1778617157,"startTime":"0","endTime":"0","summary":"SELLAS Life Sciences Q1 net loss widens on higher expensesOverviewUS biopharmaceutical developer's Q1 net loss widened amid higher operating expensesCompany ended Q1 with $107.1 mln in cash, plus $7.5","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nL1N41P1EM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SLS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635247562","title":"BRIEF-SELLAS Life Sciences Q1 Net Income USD -8.407 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2635247562","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635247562?lang=en_us&edition=fundamental","pubTime":"2026-05-13 04:05","pubTimestamp":1778616349,"startTime":"0","endTime":"0","summary":"BRIEF-SELLAS Life Sciences Q1 Net Income USD -8.407 Million\n\n\nMay 12 (Reuters) - SELLAS Life Sciences Q1 operating expenses USD 9.252 million.\n\nQ1 basic EPS USD -0.05\nQ1 operating income USD -9.252 million","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nPLXEF60F5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635724735","title":"Sellas Life Sciences Q1 Net Income USD -8.407 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2635724735","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635724735?lang=en_us&edition=fundamental","pubTime":"2026-05-13 04:05","pubTimestamp":1778616305,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nPLXEF60F5:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SLS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635247111","title":"Press Release: SELLAS Life Sciences Reports First Quarter 2026 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2635247111","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635247111?lang=en_us&edition=fundamental","pubTime":"2026-05-13 04:05","pubTimestamp":1778616300,"startTime":"0","endTime":"0","summary":"-- Contract Research Organization for the Pivotal Phase 3 REGAL Trial of Galinpepimut-S  in Acute Myeloid Leukemia  Informed the Company that 78 Events have Occurred in the Trial as of May 11, 2026; SELLAS Remains Blinded to Trial Outcomes --. -- Final Analysis of REGAL Trial of GPS in AML to be Conducted Following the 80 Event --. -- $107.1 Million in Cash and Cash Equivalents as of March 31, 2026; Additional $7.5 Million in Proceeds Received in Q2 2026 to Date through Warrant Exercises --. \"The first quarter of 2026 marked an important period for SELLAS as we continued to execute across our clinical programs while preparing for the anticipated pivotal Phase 3 REGAL trial data readout,\" said Angelos Stergiou, MD, ScD h.c., President and Chief Executive Officer of SELLAS. \"We are grateful for the ongoing commitment of the patients, caregivers, and investigators participating in the pivotal Phase 3 REGAL trial and we believe that the upcoming results, triggered by reaching the pre-speci","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SLS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635242063","title":"Sellas Life Sciences Q1 FY26 net loss widens 44.63% to $8.41 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2635242063","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635242063?lang=en_us&edition=fundamental","pubTime":"2026-05-13 04:02","pubTimestamp":1778616165,"startTime":"0","endTime":"0","summary":"Sellas Life Sciences posted a net loss of USD 8.41 million for the three months ended March 31, 2026, widening from USD 5.81 million a year earlier.Operating loss widened to USD 9.25 million from USD 6.06 million, as operating expenses climbed to USD 9.25 million from USD 6.06 million.Research and development expense rose to USD 5.13 million from USD 3.21 million, driven mainly by higher manufacturing costs tied to preparations for a potential BLA filing for GPS and higher clinical and regulatory consulting costs.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sellas Life Sciences Group Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nNDL2vLswP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SLS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631050305","title":"Solstice Minerals Limited (SLS) Gets a Buy from Canaccord Genuity","url":"https://stock-news.laohu8.com/highlight/detail?id=2631050305","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631050305?lang=en_us&edition=fundamental","pubTime":"2026-04-30 12:35","pubTimestamp":1777523720,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Paul Howard CFA from Canaccord Genuity maintained a Buy rating on Solstice Minerals Limited, with a price target of...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/solstice-minerals-limited-sls-gets-a-buy-from-canaccord-genuity-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/solstice-minerals-limited-sls-gets-a-buy-from-canaccord-genuity-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","SLS","CFA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630931836","title":"Sellas Life Sciences call volume above normal and directionally bullish","url":"https://stock-news.laohu8.com/highlight/detail?id=2630931836","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630931836?lang=en_us&edition=fundamental","pubTime":"2026-04-27 22:41","pubTimestamp":1777300909,"startTime":"0","endTime":"0","summary":"Bullish option flow detected in Sellas Life Sciences (SLS) with 7,282 calls trading, 1.8x expected, and implied vol increasing over 7 points to 130...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/sellas-life-sciences-call-volume-above-normal-and-directionally-bullish-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/sellas-life-sciences-call-volume-above-normal-and-directionally-bullish-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","SLS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627449535","title":"SAIC Helps NASA Get Artemis II Astronauts Safely to the Moon and Back","url":"https://stock-news.laohu8.com/highlight/detail?id=2627449535","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627449535?lang=en_us&edition=fundamental","pubTime":"2026-04-14 20:30","pubTimestamp":1776169800,"startTime":"0","endTime":"0","summary":"Longtime NASA partner provides vital systems analysis, flight readiness, safety, and mission assurance to accelerate human exploration to the moon and then MarsRESTON, Va., April  14, 2026 (GLOBE NEWS","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/14/3273378/0/en/SAIC-Helps-NASA-Get-Artemis-II-Astronauts-Safely-to-the-Moon-and-Back.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SAIC","NASA","BK4123","BK4139","SLS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625674620","title":"A New Era of Sports Broadcasting: Galaxy S26 Ultra Unlocks New Perspectives, Bringing Cameras Inside the Action","url":"https://stock-news.laohu8.com/highlight/detail?id=2625674620","media":"prnewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625674620?lang=en_us&edition=fundamental","pubTime":"2026-04-06 21:14","pubTimestamp":1775481240,"startTime":"0","endTime":"0","summary":"Capturing new angles like never before, Galaxy S26 Ultra's broadcast-ready capture transforms how skateboarding is filmed, experienced and delivered in real timeLOS ANGELES, April 6, 2026 /PRNewswire/ -- Samsung Electronics Co., Ltd., a global partner of Street League Skateboarding  today announced that Galaxy S26 Ultra was used to film live Street League Skateboarding  competition for the first time when it captured the SLS DTLA Takeover on April 4. Galaxy S26 Ultra's pro-grade camera redefines the role of mobile devices in sports, delivering a fresh visual experience of skateboarding that reflects the intensity of the sport itself.","market":"sh","thumbnail":"https://mma.prnewswire.com/media/2950147/Samsung_Galaxy_S26_Ultra_POV_at_SLS_DTLA_Takeover___2.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2950147/Samsung_Galaxy_S26_Ultra_POV_at_SLS_DTLA_Takeover___2.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/a-new-era-of-sports-broadcasting-galaxy-s26-ultra-unlocks-new-perspectives-bringing-cameras-inside-the-action-302734682.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLS","SLS.AU","BK7104","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624682633","title":"KBR’s Mission Technology Solutions Supports NASA’s Artemis II Mission as Astronauts Embark on Historic Return to the Moon","url":"https://stock-news.laohu8.com/highlight/detail?id=2624682633","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624682633?lang=en_us&edition=fundamental","pubTime":"2026-04-03 04:15","pubTimestamp":1775160900,"startTime":"0","endTime":"0","summary":"HOUSTON, April  02, 2026 (GLOBE NEWSWIRE) -- KBR‘s (NYSE: KBR) Mission Technology Solutions business is delivering critical services to support astronauts on NASA’s Artemis II mission as they embark o","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/02/3267843/0/en/KBR-s-Mission-Technology-Solutions-Supports-NASA-s-Artemis-II-Mission-as-Astronauts-Embark-on-Historic-Return-to-the-Moon.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999004303.SGD","LU2362540622.SGD","LU2362541513.USD","LU2362541273.HKD","SGXZ23171101.USD","NASA","KBR","BK4139","SLS","LU0053671581.USD","BK4123"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623436017","title":"Why SELLAS Life Sciences Group (SLS) Is Down 8.3% After US$150 Million ATM Offering News","url":"https://stock-news.laohu8.com/highlight/detail?id=2623436017","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623436017?lang=en_us&edition=fundamental","pubTime":"2026-03-30 11:10","pubTimestamp":1774840237,"startTime":"0","endTime":"0","summary":"SELLAS Life Sciences Group, Inc. filed a US$150 million at-the-market follow-on equity offering alongside a broad omnibus shelf registration covering common and preferred stock, debt securities, warrants, and units, shortly after reporting a narrower full-year 2025 net loss of US$26.86 million and lower basic loss per share.\nAt the same time, SELLAS is highlighting preclinical data for its CDK9 inhibitor SLS009 in acute myeloid leukemia, including activity in mutation-heavy models often...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-sls/sellas-life-sciences-group/news/why-sellas-life-sciences-group-sls-is-down-83-after-us150-mi","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-sls/sellas-life-sciences-group/news/why-sellas-life-sciences-group-sls-is-down-83-after-us150-mi","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["SLS.AU","SLS","BK4139","BK7104"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623387604","title":"These 16 stocks are a short seller's dream - likely losers no matter what the market does","url":"https://stock-news.laohu8.com/highlight/detail?id=2623387604","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623387604?lang=en_us&edition=fundamental","pubTime":"2026-03-29 01:04","pubTimestamp":1774717440,"startTime":"0","endTime":"0","summary":"Borrowing costs eat into trading profits. These stocks are less expensive to short.Certain stocks are good bets to lag the market in the coming months, according to a new study, regardless of what the market does. Sixteen of these stocks are listed in a table at the end of this column.Short sellers have good odds of turning a profit with these equities - even if the Iran conflict is soon resolved, oil prices decline, U.S. interest rates are cut, or any other events that are likely to make the market soar transpire.The 16 stocks listed below earned their spot because their shares are expensive to borrow in the share-lending market. That means relatively few short sellers are willing to consider them, which in turn means that they most likely are trading for more than they would otherwise. And that means their stock price is more likely to decline.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PDYN","CV","BK4182","BK4606","ATLN","BK4008","RXT","GETY","BK4603","BK4139","BK4082","NFE","NNEX","CD","BK4023","BK4116","EVCM","SLS","BK4161","BK4604","BK4548","BYND","BK4077","BK4138","HURA","BK4608","SERV","CRDF","BK4212","BK4144","NNE","LCID","FLYX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622826019","title":"These 16 stocks are a short seller's dream - likely losers no matter what the market does","url":"https://stock-news.laohu8.com/highlight/detail?id=2622826019","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622826019?lang=en_us&edition=fundamental","pubTime":"2026-03-27 20:05","pubTimestamp":1774613100,"startTime":"0","endTime":"0","summary":"Borrowing costs eat into trading profits. These stocks are less expensive to short.Certain stocks are good bets to lag the market in the coming months, according to a new study, regardless of what the market does. Sixteen of these stocks are listed in a table at the end of this column.Short sellers have good odds of turning a profit with these equities - even if the Iran conflict is soon resolved, oil prices decline, U.S. interest rates are cut, or any other events that are likely to make the market soar transpire.The 16 stocks listed below earned their spot because their shares are expensive to borrow in the share-lending market. That means relatively few short sellers are willing to consider them, which in turn means that they most likely are trading for more than they would otherwise. And that means their stock price is more likely to decline.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4116","BK4604","GETY","BK4144","BK4606","BK4548","EVCM","NNE","NFE","BK4182","BK4008","BK4603","BK4212","BYND","BK4138","PDYN","BK4023","CD","RXT","SLS","BK4139","CRDF","CV","BK4082","FLYX","ATLN","BK4608","HURA","NNEX","LCID","BK4077","BK4161","SERV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622000074","title":"Sims Group earnings: SLS now core to growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2622000074","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622000074?lang=en_us&edition=fundamental","pubTime":"2026-03-26 06:19","pubTimestamp":1774477150,"startTime":"0","endTime":"0","summary":"The Sims Lifecycle Services  business is now a core driver of Sims Ltd  earnings growth, making up around 40% of group EBIT in the first half of FY26 and reflecting rapid growth as hyperscaler partners increase demand.SLS contributed approximately 40% of Sims Group's underlying EBIT in H1 FY26 . Group underlying EBIT rose to A$121.1 million in H1 FY26, up from A$73.0 million in H1 FY25. FY26 SLS underlying EBIT is forecast in the range of A$165–185 million. The newly introduced \"Memory GB Sold\" metric now gives a clearer picture of SLS's growth drivers, connecting volumes directly to revenue and reflecting the business's evolving role as a global leader in circular cloud solutions. SLS has also announced an expansion in Ireland, expected to be operational from July 2026, supporting future European growth.SLS is already a material earnings driver for Sims and is uniquely positioned at the intersection of structural growth trends in technology. Our capital-light business model and strong","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"motleyfoolau_stock","url":"https://www.fool.com.au/2026/03/26/sims-group-earnings-sls-now-core-to-growth/","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2026/03/26/sims-group-earnings-sls-now-core-to-growth/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["SLS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621752839","title":"Sellas Life Sciences files automatic mixed securities shelf","url":"https://stock-news.laohu8.com/highlight/detail?id=2621752839","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621752839?lang=en_us&edition=fundamental","pubTime":"2026-03-21 05:05","pubTimestamp":1774040742,"startTime":"0","endTime":"0","summary":"17:02 EDT Sellas Life Sciences (SLS) files automatic mixed securities shelf Published first on TheFly – the ultimate source for real-time, market-m...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/sellas-life-sciences-files-automatic-mixed-securities-shelf-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/sellas-life-sciences-files-automatic-mixed-securities-shelf-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SLS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.sellaslifesciences.com","stockEarnings":[{"period":"1week","weight":0.0719},{"period":"1month","weight":0.0966},{"period":"3month","weight":0.4223},{"period":"6month","weight":2.5753},{"period":"1year","weight":2.3896},{"period":"ytd","weight":0.3846}],"compareEarnings":[{"period":"1week","weight":0.0199},{"period":"1month","weight":0.0864},{"period":"3month","weight":0.0668},{"period":"6month","weight":0.0984},{"period":"1year","weight":0.2662},{"period":"ytd","weight":0.0825}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. The company is headquartered in New York, New York.","yearOnYearQuotes":[{"month":1,"riseRate":0.416667,"avgChangeRate":-0.030636},{"month":2,"riseRate":0.5,"avgChangeRate":-0.01322},{"month":3,"riseRate":0.25,"avgChangeRate":-0.060862},{"month":4,"riseRate":0.5,"avgChangeRate":0.097703},{"month":5,"riseRate":0.75,"avgChangeRate":0.113254},{"month":6,"riseRate":0.272727,"avgChangeRate":-0.198756},{"month":7,"riseRate":0.363636,"avgChangeRate":-0.033023},{"month":8,"riseRate":0.363636,"avgChangeRate":-0.058558},{"month":9,"riseRate":0.272727,"avgChangeRate":-0.031827},{"month":10,"riseRate":0.363636,"avgChangeRate":0.051142},{"month":11,"riseRate":0.25,"avgChangeRate":-0.061889},{"month":12,"riseRate":0.25,"avgChangeRate":0.046982}],"exchange":"NASDAQ","name":"SELLAS Life Sciences Group Inc.","nameEN":"SELLAS Life Sciences Group Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"SELLAS Life Sciences Group Inc.(SLS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest SELLAS Life Sciences Group Inc.(SLS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"SELLAS Life Sciences Group Inc.,SLS,SELLAS Life Sciences Group Inc.股票,SELLAS Life Sciences Group Inc.股票老虎,SELLAS Life Sciences Group Inc.股票老虎国际,SELLAS Life Sciences Group Inc.行情,SELLAS Life Sciences Group Inc.股票行情,SELLAS Life Sciences Group Inc.股价,SELLAS Life Sciences Group Inc.股市,SELLAS Life Sciences Group Inc.股票价格,SELLAS Life Sciences Group Inc.股票交易,SELLAS Life Sciences Group Inc.股票购买,SELLAS Life Sciences Group Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"SELLAS Life Sciences Group Inc.(SLS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest SELLAS Life Sciences Group Inc.(SLS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}